BioSpace News Archive

Updated subgroup analysis in 34 heavily pretreated patients with HER2-low-expressing metastatic breast cancer demonstrated a 50.0 percent confirmed overall response rate and an 85.3 percent disease control rate with DS-8201

- First-in-human safety data presented from phase 1/2 study with U3-1402, an investigational and potential first-in-class HER3-targeting antibody drug conjugate (ADC), in patients with heavily pretreated HER3-positive metastatic breast cancer - Preliminary efficacy data demonstrated a 47 percent confirmed overall response rate and a 94 percent disease control rate with U3-1402

MDP will acquire a majority ownership position in Alcami from existing shareholder Ares Capital Corporation

Former Staples CEO Shira Goodman and Harvard CIO Anne Margulies Elected at the Annual Meeting of Stockholders to Succeed Directors Donald J. Kabat and Lawrence S. Bacow

SilverCloud Health Limited has updated the user interface (UI) for its digital mental health platform.

Health food supplement manufacturer expands UK reach with acquisition of distribution expert

Findings will be highlighted in a poster discussion at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting underway in Chicago, on Saturday, June 2, from 4:45 pm to 6:00 p.m. CDT

Vaxart, Inc. announced that Wouter Latour, M.D., president and chief executive officer of Vaxart, will present a company overview at the Jefferies 2018 Global Healthcare Conference.

FLX Bio, Inc. announced that Brian Wong, M.D., Ph.D., President and CEO will present at the Jefferies Global Healthcare Conference.

Anquetil will discuss how Portal Instruments’ connected drug-delivery system differentiates pharmaceutical company brands and creates a better healthcare experience.